Status | Study |
Completed |
Study Name: Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma Condition: Mycosis Fungicides Sezary Syndrome Date: 2008-09-05 Interventions: Other: Detection of KIR receptor by RT PCR Detection on biopsy cutaneous (3mm) and on blood sample of 30 |
Active, not recruiting |
Study Name: Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome Condition: Lymphoma Date: 2007-04-25 Interventions: Drug: lenalidomide 10 mg daily orally administered on days 1 - 21 followed by 7 days rest of a 28-day cy |
Completed |
Study Name: Effect of Denileukin Diftitox on Immune System in CTCL Patients Condition: Cutaneous T-cell Lymphoma Sezary Syndrome Date: 2005-11-15 |
Active, not recruiting |
Study Name: Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome Condition: Mycosis Fungoides Sezary Syndrome Date: 2005-09-07 Interventions: Drug: alemtuzumab |
Terminated |
Study Name: Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome Condition: Mycosis Fungoides Sezary Syndrome Date: 2005-08-08 Interventions: Drug: HuMax-CD4 (zanolimumab) Monoclonal Antibody, 12 weekly infusions. |
Completed |
Study Name: Immunization Against Tumor Cells in Sezary Syndrome Condition: Cutaneous T-cell Lymphoma Sezary Syndrome Date: 2004-12-17 Interventions: Biological: Autologous Dendritic Cell Vaccine |
Active, not recruiting |
Study Name: Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome Condition: Lymphoma Date: 2003-04-07 Interventions: Biological: alemtuzumab Will be administered as a two-hour IV infusion with a target dose of 30 milligra |
Active, not recruiting |
Study Name: Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome Condition: Mycosis Fungoides Sezary Syndrome Date: 2002-10-03 Interventions: Drug: Campath-1H |
Terminated |
Study Name: Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome Condition: Lymphoma Date: 2000-06-02 Interventions: Biological: aldesleukin |
Terminated |
Study Name: Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome Condition: Lymphoma Date: 1999-12-10 Interventions: Drug: temozolomide Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a to |